CClinicalTrials.gg
TerminatedNCT03755518FREEDOMUpdated Dec 12, 2024Results posted

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

A Phase 3 interventional study of FEDRATINIB in Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis and Myelofibrosis, sponsored by Celgene. Terminated at 35 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-12.

Sponsored by Celgene · Phase 3, Interventional, and Treatment

Why this study was terminated
Slow accrual.
Phase
Phase 3
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (post-ET MF) and Previously Treated with Ruxolitinib.

The primary objective of the study is to evaluate the percentage of subjects with at least a 35% reduction in spleen size and one of the secondary objectives is to evaluate the safety of fedratinib.

Read the detailed description

This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (post-ET MF) and Previously Treated with Ruxolitinib.

The spleen volume reduction at the end of Cycle 6 as the primary objective. The secondary objectives of the study are to further evaluate the safety and to assess and implement mitigation strategies for WE and for gastrointestinal (GI) adverse events.

The study will be at multiple centers to provide access to a broad population and have assurance the results are likely to have general applicability.

This is also conducted as an open-label study to collect efficacy and safety data with fedratinib use, no randomization or stratification will occur.

02

Conditions studied

  • Primary Myelofibrosis
  • Post-Polycythemia Vera Myelofibrosis
  • Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis

Keywords

  • Myelofibrosis (MF)
  • Primary Myelofibrosis (PMF)
  • Post-Polycythemia Vera Myelofibrosis (Post-PV)
  • Post-essential thrombocythemia Myelofibrosis (Post-ET)
  • Myeloproliferative neoplasms (MPN)
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Main Study Inclusion Criteria

  1. Subject is at least 18 years of age at the time of signing the informed consent form (ICF)
  2. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Score (PS) of 0, 1 or 2
  3. Subject has diagnosis of primary myelofibrosis (PMF) according to the 2016 World Health Organization (WHO) criteria, or diagnosis of post-ET or post-PV myelofibrosis according to the IWG-MRT 2007 criteria, confirmed by the most recent local pathology report
  4. Subject has a DIPSS Risk score of Intermediate or High
  5. Subject has a measurable splenomegaly during the screening period as demonstrated by spleen volume of ≥ 450 cm3 by MRI or CT-scan assessment or by palpable spleen measuring ≥ 5 cm below the left costal margin.
  6. Subject has been previously exposed to ruxolitinib, while diagnosed with MF (PMF, post-ET MF or post-PV MF), and must meet at least one of the following criteria (a or b)

    1. Treatment with ruxolitinib for ≥ 3 months
    2. Treatment with ruxolitinib for ≥ 28 days complicated by any of the following:

      • Development of a red blood cell transfusion requirement (at least 2 units/month for 2 months) or
      • Grade ≥ 3 AEs of thrombocytopenia, anemia, hematoma, and/or hemorrhage while on treatment with ruxolitinib
  7. Subject must have treatment-related toxicities from prior therapy resolved to Grade 1 or pretreatment baseline before start of last therapy prior to fedratinib treatment.
  8. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
  9. Subject is willing and able to adhere to the study visit schedule and other protocol requirements
  10. Participants must agree to use effective contraception

Exclusion criteria

Exclusion Criteria:

Main Study Exclusion Criteria

  1. Any of the following laboratory abnormalities:

    1. Platelets \< 50,000/μL
    2. Absolute neutrophil count (ANC) \< 1.0 x 109/L
    3. White blood count (WBC) > 100 x 10\^9/L
    4. Myeloblasts > 5 % in peripheral blood
    5. Estimated glomerular filtration rate \< 30 mL/min/1.73 m\^2 (as per the Modification of Diet in Renal Disease [MDRD] formula)
    6. Serum amylase or lipase > 1.5 x ULN (upper limit of normal)
    7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x ULN
    8. Total bilirubin > 1.5 x ULN, subject's total bilirubin between 1.5 - 3.0 x ULN are eligible if the direct bilirubin fraction is \< 25% of the total bilirubin
  2. Subject is pregnant or lactating female
  3. Subject with previous splenectomy
  4. Subject with previous or planned hematopoietic cell transplant
  5. Subject with prior history of encephalopathy, including Wernicke's
  6. Subject with signs or symptoms of encephalopathy including Wernicke's (eg, severe ataxia, ocular paralysis or cerebellar signs)
  7. Subject with thiamine deficiency, defined as thiamine levels in whole blood below normal range according to institutional standard and not corrected prior to enrollment on the study
  8. Subject with concomitant treatment with or use of pharmaceutical, herbal agents or food known to be strong or moderate inducers of Cytochrome P450 3A4 (CYP3A4), or dual CYP2C19 and CYP3A4 inhibitors
  9. Subject on any chemotherapy, immunomodulatory drug therapy (eg, thalidomide, interferon-alpha), anagrelide, immunosuppressive therapy, systemic corticosteroids > 10 mg/day prednisone or equivalent. Subjects who have had prior exposure to hydroxyurea (eg, Hydrea) in the past may be enrolled into the study as long as it has not been administered within 14 days prior to the start of fedratinib treatment
  10. Subject has received ruxolitinib within 14 days prior to the start of fedratinib
  11. Subject on treatment with myeloid growth factor (eg, granulocyte-colony stimulating factor [G-CSF]) within 14 days prior to the start of fedratinib treatment
  12. Subject with previous exposure to Janus kinase (JAK) inhibitor(s) for more than 1 cycle other than ruxolitinib treatment
  13. Subject on treatment with aspirin with doses > 150 mg daily
  14. Subject with major surgery within 28 days before starting fedratinib treatment
  15. Subject with diagnosis of chronic liver disease (eg, chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemochromatosis, non-alcoholic steatohepatitis)
  16. Subject with prior malignancy other than the disease under study unless the subject has not required treatment for the malignancy for at least 3 years prior to enrollment.

    However, subject with the following history/concurrent conditions provided successfully treated may enroll: non-invasive skin cancer, in situ cervical cancer, carcinoma in situ of the breast, incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system), or is free of disease and on hormonal treatment only

  17. Subject with uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4)
  18. Subject with known human immunodeficiency virus (HIV), known active infectious Hepatitis B (HepB), and/or known active infectious Hepatitis C (HepC)
  19. Subject with serious active infection
  20. Subject with presence of any significant gastric or other disorder that would inhibit absorption of oral medication
  21. Subject is unable to swallow capsule
  22. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
  23. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
  24. Subject has any condition that confounds the ability to interpret data from the study
  25. Subject with participation in any study of an investigational agent (drug, biologic, device) within 30 days prior to start of fedratinib treatment
  26. Subject with life expectancy of less than 6 months.
04

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Administration of Fedratinib 400mg/day

    Self-administered Investigational Product (IP) (400 mg/day) on an outpatient basis, once daily preferably with food during an evening meal at the same time each day in consecutive 4-week (28-day) cycles.

    Drug: FEDRATINIB

Interventions

  • DrugFEDRATINIB

    A potent and selective inhibitor of JAK2 kinase activity

05

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Have a ≥ 35% Spleen Volume Reduction (SVR) at End of Cycle 6

    Percentage of participants who have a ≥ 35% SVR at end of Cycle 6 as compared to baseline. Participants with a missing MRI/CT spleen volume at the end of Cycle 6 including those who meet the criteria for progression of splenomegaly before the end of Cycle 6 will be considered non-responders. Baseline value is defined as the last value or measurement taken prior to the first dose in the study

    Time frame: From First Dose to end of Cycle 6 (approximately 168 days)

Secondary outcomes

  1. Number of Participants of All Grade Adverse Events (AEs) and Grade 3/4 AEs

    Number of participants and severity of all grade adverse events (AEs) and grade 3/4 AEs as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.

    Time frame: From first dose up to 30 days post last dose. (an average of 50.3 weeks up to a maximum of 128 weeks)

  2. Number of Participants and Severity of Treatment Related All Grade Adverse Events (AEs) and Grade 3/4 AEs

    Number of participants and severity of treatment related all grade adverse events (AEs) and grade 3/4 AEs as per NCI CTCAE.

    Time frame: From first dose up to 30 days post last dose. (an average of 50.3 weeks up to a maximum of 124 weeks)

  3. Mean Change From Baseline in Hematology Laboratory Analysis - Hemoglobin

    Mean change from baseline in hematology laboratory analysis - hemoglobin

    Time frame: at Cycle 4 Day 1 and Cycle 7 Day 1

  4. Mean Change From Baseline in Hematology Laboratory Analysis - Erythrocytes

    Mean change from baseline in hematology laboratory analysis - erythrocytes. Baseline value is defined as the last value or measurement taken prior to the first dose in the study

    Time frame: at Cycle 4 Day 1 and Cycle 7 Day 1

  5. Mean Change From Baseline in Hematology Laboratory Analysis - Platelets, Leukocytes and Neutrophils

    Mean change from baseline in hematology laboratory analysis - platelets, leukocytes and neutrophils. Baseline value is defined as the last value or measurement taken prior to the first dose in the study

    Time frame: at Cycle 4 Day 1 and Cycle 7 Day 1

  6. Mean Change From Baseline in the Percentage of Blasts/Leukocytes in Hematology Laboratory Analysis

    Mean change from baseline in hematology laboratory analysis - blasts/leukocytes Baseline value is defined as the last value or measurement taken prior to the first dose in the study

    Time frame: at Cycle 4 Day 1 and Cycle 7 Day 1

  7. Mean Change From Baseline in Chemistry Parameters Analysis - ALT, AST, Amylase, Lipase

    Mean change from baseline in chemistry parameters analysis - ALT, AST, Amylase, Lipase Baseline value is defined as the last value or measurement taken prior to the first dose in the study

    Time frame: at Cycle 4 Day 1 and Cycle 7 Day 1

  8. Mean Change From Baseline in Chemistry Parameters Analysis - Creatinine

    Mean change from baseline in chemistry parameters analysis - Creatinine. Baseline value is defined as the last value or measurement taken prior to the first dose in the study

    Time frame: at Cycle 4 Day 1 and Cycle 7 Day 1

  9. Spleen Response Rate by Palpation

    Spleen response rate by palpation is the percentage of participants with a spleen response according to the IWG-MRT 2013 at the end of Cycle 6 as compared to baseline. This will be calculated for participants that have an enlarged spleen (≥ 5 cm below LCM) at baseline. Participants with a missing spleen size assessment at the end of Cycle 6 including those who meet the criteria for progression of splenomegaly before the end of Cycle 6 will be considered not to be responders.

    Time frame: From First Dose to end of Cycle 6 (approximately 168 days)

  10. Symptom Response Rate

    Symptom response rate (SRR) is defined as the percentage of participants with ≥ 50% reduction from baseline to the end of Cycle 6 in total symptom score (TSS) measured by MFSAF version 4.0. The TSS will be defined as the sum of each of the 7 symptom scores. Participants without a baseline TSS \> 0 will be considered non-evaluable (due to no place for symptom reduction) for the SRR analysis. Participants with a missing TSS at the end of Cycle 6 or who had disease progression before the end of the Cycle 6 will be considered non-responders.

    Time frame: From First Dose to end of Cycle 6 (approximately 168 days)

  11. Durability of Spleen Volume Response by MRI/CT (DR)

    Durability of spleen volume response (DR) by MRI/CT is defined as time from the first documented spleen response (ie, ≥ 35% reduction in spleen volume) to the date of subsequent progressive disease (PD) (ie, ≥ 25% increase in spleen volume from baseline) or death, whichever is earlier. In the absence an event (ie, subsequent spleen volume reduction \< 35% before the analysis is performed), the DR will be censored at the date of the last valid assessment performed before the analysis performed date. Durability of spleen volume response by MRI/CT scan will be analyzed using Kaplan-Meier method.

    Time frame: From Cycle 1 Day 1 up to 30 days after last dose (Approximately an average of 59.40 Weeks)

  12. Durability of Spleen Response by Palpation (DRP)

    Durability of spleen response by palpation (DRP) is defined as time from the date of first documented palpable spleen response, according to the IWG-MRT 2013 to the date of subsequent PD according to the IWG-MRT 2013 or death, whichever is earlier. Durability of spleen response by palpation according to the IWG-MRT 2013 criteria will be calculated for subjects that have an enlarged spleen at baseline (≥ 5 cm below LCM), and that have a spleen response by palpation. In the absence of an event (ie, no loss of spleen response by palpation) before the analysis is performed, the DRP will be censored at the date of the last valid assessment performed before the analysis performed date. Durability of spleen response by palpation will be analyzed using Kaplan-Meier (K-M) method.

    Time frame: From Cycle 1 Day 1 up to 30 days after last dose (Approximately an average of 59.32 Weeks)

  13. Durability of Symptom Response (DSR)

    Durability of symptoms response is defined as time from the first documented response in TSS (ie, reduction in TSS ≥ 50%) measured by MFSAF version 4.0 to the first documented TSS reduction \< 50%. In the absence of TSS reduction \< 50% before the analysis performed, the DSR will be censored at the date of the last valid assessment performed before the analysis performed date.

    Time frame: From Cycle 1 Day 1 up to 30 days after last dose (Approximately an average of 31.33 Weeks)

  14. Number of Participants With Grade 3 or Higher AEs: Nausea, Vomiting, Diarrhea and Encephalopathy Including Wernicke's.

    Number of participants with grade 3 or higher AEs: Nausea, Vomiting, Diarrhea and Encephalopathy including Wernicke's.

    Time frame: From first dose to end of treatment (an average of 50.3 weeks up to a maximum of 124 weeks)

  15. Number of Participants With Thiamine Levels < Lower Limit of Normal (LLN).

    Number of participants with thiamine levels \< LLN. LLN of thiamine is 70 nmol/L.

    Time frame: At Cycle 1, 2, 3, and every 3 cycles afterwards till End of Treatment (an average of 50.3 weeks up to a maximum of 124 weeks)

  16. Number of Participants With Thiamine Levels > Upper Limit of Normal (ULN).

    Number of participants with thiamine levels \> ULN. ULN of thiamine is 180 nmol/L.

    Time frame: At Cycle 1, 2, 3, and every 3 cycles afterwards till End of Treatment (an average of 50.3 weeks up to a maximum of 124 weeks)

  17. Number of Participants With Clinically Notable Laboratory Results, Grade 3 or 4

    Number of participants with clinically notable laboratory results, Grade 3 or 4

    Time frame: From first dose up to 30 days post last dose. (an average of 50.3 weeks up to a maximum of 124 weeks)

06

Results

Posted Mar 9, 2023

Participant flow

Participant flow — Overall Study
MilestoneFedratimib
Started38
Completed0
Not completed38
Withdrew: Lack of efficacy10
Withdrew: Adverse event7
Withdrew: Study terminated by sponsor5
Withdrew: Death1
Withdrew: Withdrawal by subject3
Withdrew: Progressive disease4
Withdrew: Bone marrow transplant4
Withdrew: Physicians decision1
Withdrew: Relapse1
Withdrew: Withdrawal by investigator for non compliance1
Withdrew: Withdrawal by pi1

Outcome measures

PrimaryPercentage of Participants Who Have a ≥ 35% Spleen Volume Reduction (SVR) at End of Cycle 6

Percentage of participants who have a ≥ 35% SVR at end of Cycle 6 as compared to baseline. Participants with a missing MRI/CT spleen volume at the end of Cycle 6 including those who meet the criteria for progression of splenomegaly before the end of Cycle 6 will be considered non-responders. Baseline value is defined as the last value or measurement taken prior to the first dose in the study

Time frame:
From First Dose to end of Cycle 6 (approximately 168 days)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Have a ≥ 35% Spleen Volume Reduction (SVR) at End of Cycle 6
Percentage of participantsFedratimib
Percentage of Participants Who Have a ≥ 35% Spleen Volume Reduction (SVR) at End of Cycle 625.7 (12.5 to 43.3)
SecondaryNumber of Participants of All Grade Adverse Events (AEs) and Grade 3/4 AEs

Number of participants and severity of all grade adverse events (AEs) and grade 3/4 AEs as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.

Time frame:
From first dose up to 30 days post last dose. (an average of 50.3 weeks up to a maximum of 128 weeks)
Reported as:
Count of participants · Participants
Number of Participants of All Grade Adverse Events (AEs) and Grade 3/4 AEs
ParticipantsFedratimib
All grade38
Grade 3/430
SecondaryNumber of Participants and Severity of Treatment Related All Grade Adverse Events (AEs) and Grade 3/4 AEs

Number of participants and severity of treatment related all grade adverse events (AEs) and grade 3/4 AEs as per NCI CTCAE.

Time frame:
From first dose up to 30 days post last dose. (an average of 50.3 weeks up to a maximum of 124 weeks)
Reported as:
Count of participants · Participants
Number of Participants and Severity of Treatment Related All Grade Adverse Events (AEs) and Grade 3/4 AEs
ParticipantsFedratimib
All grade34
Grade 3/413
SecondaryMean Change From Baseline in Hematology Laboratory Analysis - Hemoglobin

Mean change from baseline in hematology laboratory analysis - hemoglobin

Time frame:
at Cycle 4 Day 1 and Cycle 7 Day 1
Reported as:
Mean · g/dL
Mean Change From Baseline in Hematology Laboratory Analysis - Hemoglobin
g/dLFedratimib
cycle 4 day 1-1.16 ± 1.431
cycle 7 day 1-1.13 ± 1.127
SecondaryMean Change From Baseline in Hematology Laboratory Analysis - Erythrocytes

Mean change from baseline in hematology laboratory analysis - erythrocytes. Baseline value is defined as the last value or measurement taken prior to the first dose in the study

Time frame:
at Cycle 4 Day 1 and Cycle 7 Day 1
Reported as:
Mean · 10¹²Cells/L
Mean Change From Baseline in Hematology Laboratory Analysis - Erythrocytes
10¹²Cells/LFedratimib
cycle 4 day 1-0.60 ± 0.567
cycle 7 day 1-0.67 ± 0.609
SecondaryMean Change From Baseline in Hematology Laboratory Analysis - Platelets, Leukocytes and Neutrophils

Mean change from baseline in hematology laboratory analysis - platelets, leukocytes and neutrophils. Baseline value is defined as the last value or measurement taken prior to the first dose in the study

Time frame:
at Cycle 4 Day 1 and Cycle 7 Day 1
Reported as:
Mean · 10⁹Cells/L
Mean Change From Baseline in Hematology Laboratory Analysis - Platelets, Leukocytes and Neutrophils
10⁹Cells/LFedratimib
Baseline Platelets0 ± 0
cycle 4 day 1 - platelets13.8 ± 135.86
cycle 7 day 1 - platelets11.7 ± 131.25
cycle 4 day 1 - leukocytes-15.481 ± 21.6350
cycle 7 day 1 - leukocytes-15.127 ± 18.5744
cycle 4 day 1 - neutrophils-10.064 ± 14.2661
cycle 7 day 1 - neutrophils-10.495 ± 13.5489
SecondaryMean Change From Baseline in the Percentage of Blasts/Leukocytes in Hematology Laboratory Analysis

Mean change from baseline in hematology laboratory analysis - blasts/leukocytes Baseline value is defined as the last value or measurement taken prior to the first dose in the study

Time frame:
at Cycle 4 Day 1 and Cycle 7 Day 1
Reported as:
Mean · Percentage of blasts/leukocytes
Mean Change From Baseline in the Percentage of Blasts/Leukocytes in Hematology Laboratory Analysis
Percentage of blasts/leukocytesFedratimib
cycle 4 day 10.0 ± 1.50
cycle 7 day 1-0.2 ± 1.82
SecondaryMean Change From Baseline in Chemistry Parameters Analysis - ALT, AST, Amylase, Lipase

Mean change from baseline in chemistry parameters analysis - ALT, AST, Amylase, Lipase Baseline value is defined as the last value or measurement taken prior to the first dose in the study

Time frame:
at Cycle 4 Day 1 and Cycle 7 Day 1
Reported as:
Mean · U/L
Mean Change From Baseline in Chemistry Parameters Analysis - ALT, AST, Amylase, Lipase
U/LFedratimib
cycle 4 day 1 - ALT0.7 ± 18.49
cycle 7 day 1 - ALT7.3 ± 29.53
cycle 4 day 1 - AST-0.9 ± 8.71
cycle 7 day 1 - AST2.3 ± 11.83
cycle 4 day 1 - Amylase15.1 ± 17.17
cycle 7 day 1 - Amylase10.5 ± 15.19
cycle 4 day 1 - Lipase11.6 ± 19.22
cycle 7 day 1 - Lipase6.4 ± 13.60
SecondaryMean Change From Baseline in Chemistry Parameters Analysis - Creatinine

Mean change from baseline in chemistry parameters analysis - Creatinine. Baseline value is defined as the last value or measurement taken prior to the first dose in the study

Time frame:
at Cycle 4 Day 1 and Cycle 7 Day 1
Reported as:
Mean · umol/L
Mean Change From Baseline in Chemistry Parameters Analysis - Creatinine
umol/LFedratimib
cycle 4 day 1 - Creatinine23.9 ± 18.82
cycle 7 day 1 - Creatinine28.5 ± 23.03
SecondarySpleen Response Rate by Palpation

Spleen response rate by palpation is the percentage of participants with a spleen response according to the IWG-MRT 2013 at the end of Cycle 6 as compared to baseline. This will be calculated for participants that have an enlarged spleen (≥ 5 cm below LCM) at baseline. Participants with a missing spleen size assessment at the end of Cycle 6 including those who meet the criteria for progression of splenomegaly before the end of Cycle 6 will be considered not to be responders.

Time frame:
From First Dose to end of Cycle 6 (approximately 168 days)
Reported as:
Number · Percentage of Participants
Spleen Response Rate by Palpation
Percentage of ParticipantsFedratimib
Spleen Response Rate by Palpation16.2 (6.2 to 32.0)
SecondarySymptom Response Rate

Symptom response rate (SRR) is defined as the percentage of participants with ≥ 50% reduction from baseline to the end of Cycle 6 in total symptom score (TSS) measured by MFSAF version 4.0. The TSS will be defined as the sum of each of the 7 symptom scores. Participants without a baseline TSS \> 0 will be considered non-evaluable (due to no place for symptom reduction) for the SRR analysis. Participants with a missing TSS at the end of Cycle 6 or who had disease progression before the end of the Cycle 6 will be considered non-responders.

Time frame:
From First Dose to end of Cycle 6 (approximately 168 days)
Reported as:
Number · Percentage of participants
Symptom Response Rate
Percentage of participantsFedratimib
Symptom Response Rate44.4 (27.9 to 61.9)
SecondaryDurability of Spleen Volume Response by MRI/CT (DR)

Durability of spleen volume response (DR) by MRI/CT is defined as time from the first documented spleen response (ie, ≥ 35% reduction in spleen volume) to the date of subsequent progressive disease (PD) (ie, ≥ 25% increase in spleen volume from baseline) or death, whichever is earlier. In the absence an event (ie, subsequent spleen volume reduction \< 35% before the analysis is performed), the DR will be censored at the date of the last valid assessment performed before the analysis performed date. Durability of spleen volume response by MRI/CT scan will be analyzed using Kaplan-Meier method.

Time frame:
From Cycle 1 Day 1 up to 30 days after last dose (Approximately an average of 59.40 Weeks)
Reported as:
Median · Weeks
Durability of Spleen Volume Response by MRI/CT (DR)
WeeksFedratimib
Durability of Spleen Volume Response by MRI/CT (DR)115.1 (38.1 to NA)
SecondaryDurability of Spleen Response by Palpation (DRP)

Durability of spleen response by palpation (DRP) is defined as time from the date of first documented palpable spleen response, according to the IWG-MRT 2013 to the date of subsequent PD according to the IWG-MRT 2013 or death, whichever is earlier. Durability of spleen response by palpation according to the IWG-MRT 2013 criteria will be calculated for subjects that have an enlarged spleen at baseline (≥ 5 cm below LCM), and that have a spleen response by palpation. In the absence of an event (ie, no loss of spleen response by palpation) before the analysis is performed, the DRP will be censored at the date of the last valid assessment performed before the analysis performed date. Durability of spleen response by palpation will be analyzed using Kaplan-Meier (K-M) method.

Time frame:
From Cycle 1 Day 1 up to 30 days after last dose (Approximately an average of 59.32 Weeks)
Reported as:
Median · Weeks
Durability of Spleen Response by Palpation (DRP)
WeeksFedratimib
Durability of Spleen Response by Palpation (DRP)134.9 (33.3 to NA)
SecondaryDurability of Symptom Response (DSR)

Durability of symptoms response is defined as time from the first documented response in TSS (ie, reduction in TSS ≥ 50%) measured by MFSAF version 4.0 to the first documented TSS reduction \< 50%. In the absence of TSS reduction \< 50% before the analysis performed, the DSR will be censored at the date of the last valid assessment performed before the analysis performed date.

Time frame:
From Cycle 1 Day 1 up to 30 days after last dose (Approximately an average of 31.33 Weeks)
Reported as:
Median · Weeks
Durability of Symptom Response (DSR)
WeeksFedratimib
Durability of Symptom Response (DSR)20.1 (11.0 to 48.0)
SecondaryNumber of Participants With Grade 3 or Higher AEs: Nausea, Vomiting, Diarrhea and Encephalopathy Including Wernicke's.

Number of participants with grade 3 or higher AEs: Nausea, Vomiting, Diarrhea and Encephalopathy including Wernicke's.

Time frame:
From first dose to end of treatment (an average of 50.3 weeks up to a maximum of 124 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or Higher AEs: Nausea, Vomiting, Diarrhea and Encephalopathy Including Wernicke's.
ParticipantsFedratimib
Nausea0
Vomitting0
Diarrhea0
Encephalopathy0
Wernickes Encephalopathy0
SecondaryNumber of Participants With Thiamine Levels < Lower Limit of Normal (LLN).

Number of participants with thiamine levels \< LLN. LLN of thiamine is 70 nmol/L.

Time frame:
At Cycle 1, 2, 3, and every 3 cycles afterwards till End of Treatment (an average of 50.3 weeks up to a maximum of 124 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Thiamine Levels < Lower Limit of Normal (LLN).
ParticipantsFedratimib
Cycle 10
Cycle 22
Cycle 32
Cycle 60
Cycle 90
Cycle 120
Cycle 150
Cycle 180
Cycle 210
Cycle 240
Cycle 270
Cycle 300
Cycle 330
Cycle 360
Cycle 390
Cycle 420
Cycle 450
Cycle 480
Cycle 510
cycle 540
End of Treatment1
Total number of participants with thiamine <LLN5
SecondaryNumber of Participants With Thiamine Levels > Upper Limit of Normal (ULN).

Number of participants with thiamine levels \> ULN. ULN of thiamine is 180 nmol/L.

Time frame:
At Cycle 1, 2, 3, and every 3 cycles afterwards till End of Treatment (an average of 50.3 weeks up to a maximum of 124 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Thiamine Levels > Upper Limit of Normal (ULN).
ParticipantsFedratimib
Cycle 121
Cycle 29
Cycle 39
Cycle 66
Cycle 95
Cycle 124
Cycle 157
Cycle 184
Cycle 214
Cycle 243
Cycle 272
Cycle 302
Cycle 332
Cycle 360
Cycle 392
Cycle 421
Cycle 451
Cycle 483
Cycle 511
Cycle 540
End of Treatment9
Total number of participants with thiamine > ULN28
SecondaryNumber of Participants With Clinically Notable Laboratory Results, Grade 3 or 4

Number of participants with clinically notable laboratory results, Grade 3 or 4

Time frame:
From first dose up to 30 days post last dose. (an average of 50.3 weeks up to a maximum of 124 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Notable Laboratory Results, Grade 3 or 4
ParticipantsFedratimib
GFR from Creatinine adjusted for BSA (mL/min/1.73m²)7
Gamma Glytamyl Transferase (U/L)2
Lipase (U/L)2
Potassium (mmol/L)1
Sodium (mmol/L)4
Triglycerides (mmol/L)1
Hemoglobin (g/dL)20
Leukocytes (10⁹/L)5
Lymphocytes (10⁹/L)7
Neutrophils, Segmented (10⁹/L)4
Neutrophils, Segmented and Band Form (10⁹/L)2
Platelets (10⁹/L)10
Prothrombin INR (ratio)1

Adverse events

Collected over Adverse Events: From first dose up to 30 days post last dose. (An average of 50.3 weeks up to a maximum of 124 weeks) All-Cause Mortality: From first dose up to LPLV PE final Database lock: approximately 56 Months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fedratinib16/38 (42.1%)22/38 (57.9%)38/38 (100%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventFedratinib
PneumoniaInfections and infestations4/38
Cardiac failure congestiveCardiac disorders2/38
Gastric haemorrhageGastrointestinal disorders2/38
HyperkalaemiaMetabolism and nutrition disorders2/38
Acute kidney injuryRenal and urinary disorders2/38
AnaemiaBlood and lymphatic system disorders1/38
NeutropeniaBlood and lymphatic system disorders1/38
SplenomegalyBlood and lymphatic system disorders1/38
Atrial fibrillationCardiac disorders1/38
Atrioventricular block completeCardiac disorders1/38
Most frequent other events
Showing 10 of 105
Most frequent other events
EventFedratinib
AnaemiaBlood and lymphatic system disorders23/38
ConstipationGastrointestinal disorders19/38
DiarrhoeaGastrointestinal disorders17/38
NauseaGastrointestinal disorders16/38
ThrombocytopeniaBlood and lymphatic system disorders15/38
Blood creatinine increasedInvestigations14/38
FatigueGeneral disorders12/38
DyspnoeaRespiratory, thoracic and mediastinal disorders12/38
Oedema peripheralGeneral disorders10/38
DizzinessNervous system disorders10/38

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Fedratimib
Mean68.4 ± 7.69
Sex: Female, Male
Sex: Female, Male(Participants)Fedratimib
Female16
Male22
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Fedratimib
Hispanic or Latino0
Not Hispanic or Latino37
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Fedratimib
American Indian or Alaska Native0
Asian5
Native Hawaiian or Other Pacific Islander0
Black or African American1
White30
More than one race0
Unknown or Not Reported2
EE Population
EE Population(Participants)Fedratimib
Number35
MFSAF Population
MFSAF Population(Participants)Fedratimib
Number36
Palpation evaluable population
Palpation evaluable population(Participants)Fedratimib
Number37
07

Study locations

35 sites
  • Local Institution - 117
    Aurora, Colorado 80045, United States
  • Local Institution - 126
    Miami, Florida 33176, United States
  • Local Institution - 113
    Augusta, Georgia 30912, United States
  • Local Institution - 112
    Chicago, Illinois 60612, United States
  • Local Institution - 109
    Chicago, Illinois 60637, United States
  • Local Institution - 121
    Park Ridge, Illinois 60068, United States
  • Local Institution - 100
    Kansas City, Kansas 66160-7314, United States
  • Local Institution - 123
    Baltimore, Maryland 21229-5299, United States
  • Local Institution - 118
    Bethesda, Maryland 20817, United States
  • Local Institution - 127
    Columbia, Maryland 21044, United States
  • Local Institution - 103
    Ann Arbor, Michigan 48109, United States
  • Local Institution - 101
    Saint Louis, Missouri 63110, United States
  • Local Institution - 128
    Newark, New Jersey 07112-2027, United States
  • Local Institution - 130
    Brooklyn, New York 11212, United States
  • Local Institution - 115
    New York, New York 10029, United States
  • Local Institution - 124
    New York, New York 10032, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Local Institution - 105
    Chapel Hill, North Carolina 27514, United States
  • Local Institution - 114
    Durham, North Carolina 27705, United States
  • Local Institution - 111
    Cincinnati, Ohio 45219, United States
  • Local Institution - 106
    Pittsburgh, Pennsylvania 15224, United States
  • Local Institution - 108
    Sioux Falls, South Dakota 57105, United States
  • Local Institution - 119
    Dallas, Texas 75390-8852, United States
  • Local Institution - 132
    Fort Worth, Texas 76104, United States
  • Local Institution - 110
    Houston, Texas 77303, United States
  • Local Institution - 120
    San Antonio, Texas 78229, United States
  • Local Institution - 116
    Seattle, Washington 98109, United States
  • Local Institution - 129
    Madison, Wisconsin 53792-2454, United States
  • Local Institution - 203
    Vancouver, British Columbia V6Z 2A5, Canada
  • Local Institution - 207
    London, Ontario N6C 6B5, Canada
  • Local Institution - 205
    Ottawa, Ontario K1H 8L6, Canada
  • Local Institution - 200
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 201
    Montreal, Quebec H1T 2M4, Canada
  • Local Institution - 202
    Montreal, Quebec H3T 1E2, Canada
  • Local Institution - 204
    Sherbrooke, Quebec J1K 2R1, Canada
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Apr 21, 2021

Documents are hosted by the registry — open the source record to download them.

09

Registry details

Key details

Study ID
NCT03755518
Lead sponsor
Celgene
Collaborators
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
Responsible party
Sponsor
First posted
Nov 28, 2018
Start date
Mar 27, 2019
Primary completion
Nov 26, 2021
Completion
Nov 8, 2023
Results posted
Mar 9, 2023
Last update
Dec 12, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion